What is the Potential of Stem Cell Treatment for PD? (YouTube Webinar)

This webinar is a recording of a live broadcast that took place in June 2019 and consisted of a panel discussion on cell-based therapy for PD. Chairing the panel is Professor Patrik Brundin. The panel of experts includes Gaynor Edwards, a person affected by PD; Parkinson’s neurologist, Clair Henchcliffe and Dr. Roger Barker, consultant neurologist. The panel discusses what kind of stem-cells exist; the source of stem-cells; the uses of stem-cells, and specifically dopamine stem-cells. The panel talks about current trials and the timeline for when stem-cells will be a viable treatment for PD. One of the issues raised is whether we will be able to produce stem-cells in large enough quantities. The panel of experts takes questions from viewers and gives answers on subjects like stem-cell tourist and the cost of treatment. The final word on the subject is that despite the cost of potential stem-cell treatment it will save money spent on the medical care of untreated patients in the long term.

Review of Possible Use of a Keto Diet in PD Treatment

A review focused on the role of ketogenic diets in neurodegenerative diseases (including PD) was published in the MDPI journal Nutrient in 2019. The goal of the review was to assess the effectiveness of ketogenic diets as part of therapy for neurodegenerative diseases. In PD, dopaminergic neurons in the substantia nigra are affected by a degeneration process leading to motor and non-motor disturbances. The available results of research projects dealing with the use of the KD and ketone bodies in neurodegenerative diseases are fairly promising. At the same time, the majority of studies reviewed were employed in vitro or by using animal models. The number of studies with human participation is rather small, and those that exist feature relatively short therapy duration periods.

Source: Role of Ketogenic Diets in Neurodegenerative Diseases (Alzheimer’s Disease and Parkinson’s Disease)

Interview with Dale E. Bredesen, md on Reversing Cognitive Decline

In 2015 Dale E. Bredesen md was interviewed by IMCJ about reversing cognitive decline. Dr. Bredesen is an expert in mechanisms of neurodegenerative diseases. About the monotherapeutic approach to degenerative diseases, the doctor said that a cocktail of therapies can be more successful. We now are recognizing multiple subtypes of Alzheimer’s disease. Dr. Bredesen sees the underlying molecular mechanistics of what we refer to as Alzheimer’s disease, as 3 subtypes, two of which are not illnesses. If you look at the molecular mechanistics, what you see is that this is actually a well-orchestrated, non-disease, strategic downsizing based on many different inputs and a mismatch of those with what is actually required to maintain those synapses and to continue with the remodeling that goes on throughout life. Bredesen approaches this with a systematic protocol of lifestyle and nutritional interventions which was published in 2014 in the journal Aging. Dr. Bredesen: “You need to look at a number of critical features such as things like metal homeostasis and proteostasis and insulin resistance, which have been the subject of a tremendous amount of research and, of course, specific inflammatory pathways.”

Source: Dale E. Bredesen, md: Reversing Cognitive Decline

Fact Sheet: Dietary Supplements for Primary Mitochodrial Disorders

NIH publishes a fact sheet for health professionals on dietary supplements for primary mitochondrial disorders. The fact sheet summarizes published scientific trials, other studies, and reports on the use of dietary supplements to treat primary mitochondrial disorders. The most common ingredients in dietary supplements used in PMD therapy include vitamin C, vitamin E, and alpha-lipoic acid; electron donors and acceptors, such as CoQ10and riboflavin; compounds that can be used as alternative energy sources, such as creatine; and compounds that can conjugate or bind mitochondrial toxins, such as carnitine. A combination of these products is commonly called a mitochondrial cocktail. However, there are many combinations and dosages so the term is nonspecific and nondescriptive. Drug interaction needs to be taken into consideration as well as the level of evidence of efficiency, quality of ingredients, and dosage.

Source: Dietary Supplements for Primary Mitochondrial Disorders – Health Professional Fact Sheet

Review: The Role of Dietary Fat in Treatment of Brain Diseases

A review published in the Current Neuropharmacology journal in 2018 looked at the impact of dietary fats on brain function. It also examined gut-brain communication through microbiota; the impact of probiotics and prebiotics on brain functions; SCFA’s, microbiota, and neuroinflammation. It reviewed lipid sensing, satiety, and processing of hedonic food; the impact of diet on the hypo-thalamic control of reproduction; neuroprotective effects of N-3 PUFAs; dietary PUFAs, brain PUFAs and the role of PUFAs. The results of this review revealed that dietary fats are both friends and foes for brain functions. However, dietary manipulation for the treatment of brain disorders is not just a promise for the future, but a reality. In fact, the clinical relevance of the manipulation of dietary lipids, as for KDs, is well-known and currently in use for the treatment of brain diseases.

Source: Impact of Dietary Fats on Brain Functions
LGIT safe (see 305)

Magnesium to prevent and reverse Aurtic stenosis and calcification in general

the SEM data show that the protein-protein cross-linking bonds are the starting sites of calcification. In addition, substitution of Ca2+ cations by Mg2+ cations leads to the formation of amorphous hydroxyapatite, preventing aortic valve stenosis, which suggests that treatment with magnesium salts may reduce stenosis of aortic valves…
iv.iiarjournals.org/content/28/1/91.full

We observed strong, favorable associations between higher self-reported total (dietary and supplemental) magnesium intake and lower calcification of the coronary arteries…
www.ncbi.nlm.nih.gov/pmc/articles/PMC3957229/

Studies showed that a calcium to magnesium intake ratio <2.8 is critical for optimal health, supporting a long-held but non–evidence-based recommendation that the calcium to magnesium ratio should be close to 2. Increasing calcium intakes in the United States since 1977 have resulted in a calcium to magnesium ratio >3.0 since 2000, coinciding with increasing rates of T2D and colorectal cancer. US studies assessing oral magnesium therapy or dietary magnesium intakes showed beneficial effects of dietary magnesium in CVD, T2D, and cancers, although similar studies in populations with lower calcium to magnesium ratios (≥1.7) reported the opposite…
www.ncbi.nlm.nih.gov/pmc/articles/PMC4717874/

 

David Sinclair personal anti aging supplements protocol

NMN 1 gr with food(fat) in the morning, proven to raise NAD

Reversatol 0.5 gr (checkout Uleic acid – olive oil alternative)

Metformin 1 gr at night (checkout supplement alternative Berberine )

#q1: checkout this supplement
il.iherb.com/pr/Thorne-Research-ResveraCel-60-Capsules/69377

#q2: interaction with Warfarin

Avoid mamals due to TAMO
From 4:30 here:

another list,from fastlifehacks.com/david-sinclair-supplements/

David Sinclair Takes:

Resveratrol – 1g/daily – mornings with yogurt (see where to buy)
Nicotinamide Mononucleotide (NMN) – 1g/daily – mornings (see where to buy)
Metformin (prescription drug) – 1g/daily in the evenings – except on days when exercising
Multivitamins? Only vitamin D3 with K2, he aims to get the rest from his diet
Statin (prescription drug) – taken since his early 20s due to family history of cardiovascular disease
Aspirin – 83mg daily

make a list according to this guy

checkout Uleic vs resveratrol

Risk:

Metformin may increase risk of PD and other neurodegenerative disease

Infection by Prion-like infection α-synuclein

from food:

www.ncbi.nlm.nih.gov/pmc/articles/PMC5701169/

  • so human source probably also possible
  • leaky gut probably a factor

According to research from John Hopkins, Duke University, and Utah State University, caregivers of someone with neurodegenerative disease are six times more likely to develop the condition themselves. Neurodegenerative disease is a spectrum disease.

Resection of the vagus nerve before rotenone treatment stopped the spread of PD-like pathology.13 Taken together, these data support the intriguing Braak and prion hypotheses of PD development.